Indefinite Delivery Contract 75D30123D16727
Award Date
7/1/23
Last Date to Order
6/30/24
Federal Agency
CDC Pittsburgh
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325411 - Medicinal and Botanical Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC to procure a variety of adult vaccines over a 1-year period from July 1, 2021 to June 30, 2022. The $156,027,900 multiple award IDC contains no set-aside designation and requires delivery within 15 business days of order placement to destinations across the United States to support state health departments and immunization programs. The original solicitation...
This indefinite-delivery, indefinite-quantity (IDIQ) contract was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, to Glaxosmithkline, LLC, a pharmaceutical company, for the purchase of 12 standard adult vaccines. The $172.4 million contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and does not utilize any set-asides. The vaccines, which include influenza, hepatitis, pneumococcal, and...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) has awarded a 5-year, $154.3 million indefinite delivery, indefinite quantity (IDIQ) contract to Glaxosmithkline, LLC for the provision of various adult vaccines. The contract period of performance is from July 1, 2024 to June 30, 2025, with vaccines ordered via the CDC's Vaccine Tracking System (VTrckS) using a fair opportunity process. The required vaccine types include...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to provide a wide range of pediatric vaccines over a period of performance from April 1, 2024 to March 31, 2025. The contract has a ceiling value of $1,334,738,300 and is part of the CDC's National Center for Immunization and Respiratory Diseases (NCIRD) effort to support pediatric immunization programs under...
The federal contract IDV award is for the supply of various adult vaccines to the Centers for Disease Control and Prevention (CDC) for the period of July 1, 2023 through June 30, 2024. The contract was awarded to Grifols USA LLC, a global healthcare company specializing in the manufacturing and distribution of plasma-derived medicines and pharmaceutical supplies. The contract has a ceiling value of $1,842,400.00 and includes the supply of 12 different adult vaccines, including hepatitis,...
The indefinite delivery contract (IDC) 75D30120D08572 was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC for the provision of vaccines for adults. The $131,225,875 multiple award contract has a period of performance through June 30, 2021. Glaxosmithkline, a pharmaceutical company, will supply a range of vaccines and antiviral medications to support disease prevention efforts, immunization programs, and healthcare services for various U.S. government...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Pfizer Inc. for the purchase of various adult vaccines. The $118.2 million contract, running from July 1, 2024 to June 30, 2025, covers a diverse array of vaccines including Hepatitis, HPV, Measles/Mumps/Rubella, Meningococcal, Mpox, Pneumococcal, and Varicella. The contract does not utilize any set-asides and allows for...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian agency, to Glaxosmithkline Holdings (Americas) Inc. as the prime contractor. The contract has a ceiling value of $261,469,025.27 and a period of performance ending on June 30, 2011. The purpose of this IDC is to provide adult vaccines, as part of the CDC's Adult Vaccine Contract 2010 - 2011 program. The contract was not set aside for any specific business category. It was...
The Centers for Disease Control and Prevention (CDC) has awarded Pfizer Inc. an Indefinite Delivery Contract (IDC) for the supply of various adult vaccines to support immunization programs under Section 317(j) of the Public Health Service Act. The $103,060,230.33 contract, which runs from July 1, 2023 to June 30, 2024, covers a range of vaccines including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles-mumps-rubella, meningococcal...
The Centers for Disease Control and Prevention awarded multiple indefinite-delivery, indefinite-quantity contracts to Pfizer Inc. for the delivery of various adult vaccines. The contracts have a one year period of performance from July 1, 2022 to June 30, 2023 and a combined potential value of $62.2 million. Through these contracts, Pfizer will provide 12 standard adult vaccines to the CDC including hepatitis A & B, pneumococcal, tetanus/diphtheria, herpes zoster, Tdap, MMR, meningococcal,...